Purepac cefadroxil

Executive Summary

Approved Jan. 5, Purepac's cefadroxil 500 mg caps will be available soon, the company said. Purepac's parent company, Kalipharma, filed a suit in July seeking a declaratory judgment that Bristol's cefadroxil patent is invalid. Purepac received the second cefadroxil ANDA approval following Zenith's in March 1987. Bristol took Zenith to court for patent infringement and the claim was dropped after a consent order was handed down ("The Pink Sheet" June 1, 1987 "In Brief"). Zenith said it is not marketing cefadroxil.